2021-11-12-港交所-中国再生医学_2021年第三季季度报告_46页_619kb

Financial Summary of China Regenerative Medicine International Limited (2021 Q3)

• Company Background: A Cayman Islands exempted company listed on Hong Kong GEM exchange under stock code 8158. Delisted subsidiaries include those in dermatology, ophthalmology, stomatology, cell services, and cosmetics.

• Financial Highlights:

  • Revenue for the first nine months of 2021 increased by 85.4% to approximately HK$199.9 million from HK$107.8 million.
  • Revenue growth driven by expanded sales network in mainland China and new Hong Kong brands.
  • Gross profit rose by ~8.9% to HK$32.9 million, but gross profit margin dropped from 27.96% to 16.46% due to higher indirect costs (e.g., sales staff commissions).
  • Selling expenses surged 3100% to HK$3.2 million, while administrative expenses increased by 12.4% to HK$39.9 million.

• Business Outlook:

  • Focus on expanding operations in regenerative medicine and related medical devices.
  • Continue measures to improve operational performance and explore capital raising options, including acquisitions.

• Other Information:

  • Listed under GEM (Higher Investment Risk), suitable for small/mid-sized companies.
  • Affected by COVID-19; received rental concessions for unexpected gains.
  • Completed disposal of multiple subsidiaries including joint ventures and sales loans.